The fungal gut microbiota in pediatric-onset multiple sclerosis.

Evidence suggests that the gut microbiome may play a role in multiple sclerosis (MS). However, the majority of the studies have focused on gut bacterial communities; none have examined the fungal microbiota (mycobiota) in persons with pediatric-onset multiple sclerosis (POMS). We examined the gut mycobiota in persons with and without POMS through a cross-sectional examination of the gut mycobiota from 46 participants' stool samples (three groups: 18 POMS, 13 acquired monophasic demyelinating syndromes [monoADS], and 15 unaffected controls).

Exploiting Vector Pattern Diversity of Molecular Scaffolds for Cheminformatics Tasks in Drug Discovery.

Chemical diversity is challenging to describe objectively. Despite this, various notions of chemical diversity are used throughout the medicinal chemistry optimization process in drug discovery. In this work, we show the usefulness of considering exploited vectors during different phases of the drug design process to provide a quantitative and objective description of chemical diversity.

A comparative life-cycle assessment and cost analysis of biofilters amended with sludge-based activated carbon and commercial activated carbon for stormwater treatment.

Environmental and economic issues resulting from the unsustainable management of sewage sludge from wastewater have necessitated the development of eco-friendly sewage sludge disposal methods, whereas stormwater effluent contains tremendous amounts of pollutants. This study compares the feasibility and environmental impacts associated with incorporating biofilters with sludge-based activated carbon (SBAC) versus commercial activated carbon (CAC) for stormwater treatment. The results demonstrate that the construction and disposal life-cycle stages are the dominant contributors to several environmental impact categories, including resource scarcity, carcinogenic toxicity, terrestrial ecotoxicity, and ozone formation indicators.

HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies.

CCT251236 , a potent chemical probe, was previously developed from a cell-based phenotypic high-throughput screen (HTS) to discover inhibitors of transcription mediated by HSF1, a transcription factor that supports malignancy. Owing to its activity against models of refractory human ovarian cancer, was progressed into lead optimization. The reduction of P-glycoprotein efflux became a focus of early compound optimization; central ring halogen substitution was demonstrated by matched molecular pair analysis to be an effective strategy to mitigate this liability.